𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma

✍ Scribed by Shinichi Toyooka; Toshimi Takano; Takayuki Kosaka; Katsuyuki Hotta; Keitaro Matsuo; Shuji Ichihara; Yoshiro Fujiwara; Junichi Soh; Hiroki Otani; Katsuyuki Kiura; Keisuke Aoe; Yasushi Yatabe; Yuichiro Ohe; Tetsuya Mitsudomi; Hiroshi Date

Book ID
108584082
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
226 KB
Volume
99
Category
Article
ISSN
1347-9032

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of epidermal growth f
Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
✍ Gilberto de Lima Lopes Jr.; Joel E. Segel; Daniel S. W. Tan; Young K. Do; Tony M 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 870 KB

## Abstract ## BACKGROUND: Epidermal growth factor receptor (EGFR) testing and first‐line therapy with gefitinib for patients with activating mutations is quickly becoming the standard option for the treatment of advanced lung adenocarcinoma. Yet, to date, little is known about the cost‐effectiven